Lancet Diabetes & Endocrinology

Article	Citations
Direct-to-consumer services: improving access to care for people with diabetes and obesity	1088
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale	954
South Africa to produce insulin for Africa in 2024	867
Reassessing driving safety in diabetes	634
Better testing and labelling of drugs for people with obesity	588
Anand Hardikar: a scientific nomad searching for the truth	579
What's preventing us from curbing the obesity crisis?	489
A framework for improving diabetes care in humanitarian emergencies	422
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial	279
Artificial intelligence and diabetes: time for action and caution	243
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2	242
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98	232
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity	231
Specific cortisol blockade in Cushing's syndrome	219
Implications of technology guidelines for low-income and middle-income countries	219
Clinical features, investigation, and management of Addison's disease	201
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?	196
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial	191
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality	190
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p	186
Artificial intelligence for interpreting diabetes data using clinician-curated benchmarks	179
Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study	175
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions	171
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice	165
Type 1 diabetes screening: need for ethical, equity, and health systems perspective	165

World Health Assembly ratifies first global diabetes targets	164
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial	160
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study	130
What does renal failure teach us about our National Health System?	130
Challenging diabetes stigma starts and ends with all of us	127
Glycaemic index as part of the diabetes prevention strategy	126
The role of nurses in diabetes care: challenges and opportunities	119
Cardiovascular mortality trends among people with and without diabetes	115
A roadmap for integrating mental health and diabetes services	113
Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss	113
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials	112
3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial	110
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin	107
Healthy weight for the next generation's health in China	105
The urgent need for a diabetes data rights charter	101
Rising diabetes diagnosis in long COVID	100
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing	99
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply	99
Putting wellbeing at the core of diabetes care	99
Explaining the high rate of progression from prediabetes to type 2 diabetes in China	98
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-7	97
Correction to Lancet Diabetes Endocrinol 2025; published online Nov 19. https://doi.org/10.1016/S2213-8587(25)00289-X	97
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses	95
Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England	93
Diabetes and mental health	92
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history	91
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial	90
The promise and hope of GLP-1 receptor agonists	89
The uncomfortable truth about kidney disease in type 1 diabetes	89
Correction to Lancet Diabetes Endocrinol 2025; 13: 935–48	85
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study	85
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis	84
Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement	81
Understanding the mechanism of prediabetes remission in young people	80
CONCEPTT to care: the science of implementation in diabetes care	80
Gender equality: timely and timeless	77
Diabetes: knowing your risk matters	77
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction	76
Improving HbA1c levels with advanced hybrid closed-loop therapy	75
Is it time to re-assess the development of thyroid function reference ranges?	75
A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international	75
The long and winding road to precision diabetology	74
Bothersome vasomotor symptoms: a potential early clinical marker of perimenopause?	74
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–17	73
Blood pressure control according to type 2 diabetes status	72
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–83	71
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–13	69
Male hypogonadism: pathogenesis, diagnosis, and management	68
Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study	68
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors	68

Glucagon, from past to present: a century of intensive research and controversies	67
Staging prediabetes and type 2 diabetes: the time to start is now	67
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international	65
GLP-1 receptor agonists for obesity: eligibility across 99 countries	63
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants	62
Hypothalamic obesity: from basic mechanisms to clinical perspectives	62
Improving support for university students with type 1 diabetes	62
Central diabetes insipidus from a patient's perspective	60
On the occasion of International Women's Day	59
Chronicling insulin from discovery to crisis	59
Diagnosing diabetes in African populations: a twist in the tale	58
TB Joshua and his megachurch: fake medical miracles and abuse in Nigeria	55
Vitamin D and fractures	54
Sleep your way to better metabolic health	54
Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic β-cell function pretransplant	54
USP8 genotype and tumour size as predictors for recurrence in Cushing's disease	54
Embracing multiplicity in global diabetes estimation methods	53
Mendelian randomisation and vitamin D: the importance of model assumptions – Authors' reply	52
Embracing community sport to promote global health	52
World Autism Awareness Day: autism and metabolic health	51
Has the WHO Model Essential Medicines List lost its way?	51
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat	50
Screening type 1 diabetes and celiac disease by law	50
Efficacy and safety of automated insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial	50
Teplizumab approval for type 1 diabetes in the USA	49
Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-b	49
GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study	49
Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data	49
Management of menopause: a view towards prevention	48
Young adult-onset type 2 diabetes heralds a poor prognosis	48
Effect of surgical versus conservative management on cardiovascular outcomes in patients with bilateral adrenal tumours and cortisol excess: an international, retrospective cohort study	48
Insulin regimens during type 1 diabetes pregnancy	47
Automated insulin delivery postpartum: insights from the AiDAPT study extension	47
Methodological considerations in D-health cancer mortality results – Authors' reply	47
Correction to Lancet Diabetes Endocrinol 2022; 10: 668–80	47
Correction to Lancet Diabetes Endocrinol 2025; 13: 909–10	46
Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study	45
More options for young children with type 1 diabetes	45
Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study	45
Technology for type 1 diabetes: what impact will it have?	45
Does siRNA therapy against ANGPTL3 bring new hope in homozygous familial hypercholesterolaemia?	44
Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 nati	44
Correction to Lancet Diabetes Endocrinol 2024; 12: 233–46	44
Blood glucose targets in the critically ill: is one size fits all still appropriate?	44
Decision making in differences of sex development/intersex care in the USA: bridging advocacy and family-centred care	44
ORION-3: delivering lipid lowering treatment for longer	43
MarÍa José Redondo: rethinking type 1 diabetes	43
11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050	43
Diabetes and cancer in the age of multimorbidity	42
Explaining the high rate of progression from prediabetes to type 2 diabetes in China – Authors' reply	42
Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study	42
An inclusive approach to people with disabilities in diabetes care and education	42
How clinically relevant is statin-induced diabetes?	40
From reproduction to metabolism: FSH as a key modulator in menopause	40
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	40
Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2023	40
Causal inference in perinatal epidemiology: big data's false promises	39
Implications of microplastics as emerging endocrine disruptors	38
Impact of higher BMI on cardiometabolic risk: does height matter?	38
Disparities in fragility fracture and osteoporosis care in Africa	38
Addressing health and demographic challenges in Japan's ageing society	38
Life stage transitions for people with type 1 diabetes	37
Enhancing global access to diabetes medicines: policy lessons from the HIV response	36
Analogue insulin, GLP-1, and the WHO Model Essential Medicines List	36
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial	35
Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	35
Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind,	35
Type 1 diabetes in diverse ancestries and the use of genetic risk scores	35
Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial	35
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial	35
Risks and burdens of incident diabetes in long COVID: a cohort study	34
Redefining obesity: advancing care for better lives	34
Disease modifying therapies in diabetes and endocrinology	33
Iodine deficiency in Europe: vigilance and action required	33
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial	33
Mendelian randomisation and vitamin D: the importance of model assumptions	33
What's in a decade?	32
The potential role for artificial intelligence in fracture risk prediction	32
Correction to Lancet Diabetes Endocrinol 2026; 14: 317–26	30
From prominent corneal nerves to multiple endocrine neoplasia type 2B	30

Improving type 1 diabetes care globally: the importance of medical education	30
Setmelanotide: new promise for the treatment of hypothalamic obesity?	30
Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals	30
The growing global burden of thyroid cancer overdiagnosis	29
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study	29
Task shifting and task sharing in paediatric type 1 diabetes care: a global survey	29
The evolutionary basis for type 2 diabetes prevalence in the Arabian Peninsula	28
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis	28
Sleep: a neglected public health issue	28
Correction to Lancet Diabetes Endocrinol 2022; 10: 741–60	28
Incretins and the cardiovascular system: bridging digestion with metabolism	28
Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple	27
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials	27
Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis	27
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel	27
Sex differences in familial hypercholesterolaemia	27
Low visceral fat and kidney disease risk in men with diabetes	26
Heterogeneity in type 2 diabetes trajectories: informing public health approaches	26
Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control study	25
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial	25
Maternal thyroid hypofunction and gestational diabetes risk	25
Correction to Lancet Diabetes & Endocrinology 2026; 14: 105–08	24
From survival to freedom: redefining success in type 1 diabetes	24
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes	23
Prediabetes remission and cardiovascular morbidity and mortality: post-hoc analyses from the Diabetes Prevention Program Outcome study and the DaQing Diabetes Prevention Outcome study	23
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicent	23
Multi-ancestry polygenic risk scores for the prediction of type 2 diabetes and complications in diverse ancestries	23
Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial	23
Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes	23
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial	22
Lessons to learn from the 2024 NICE guideline on adrenal insufficiency	22
A global plastics treaty to protect endocrine health	22
Bariatric surgery in children with obesity and type 2 diabetes	22
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	22
Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?	22
The double burden of poor diets	22
Endocrine health in survivors of adult-onset cancer	22
Achieving replicable subphenotypes of adult-onset diabetes – Authors' reply	22
From research to policy: still a long way to go	22
SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?	21
More liberal use of bilateral adrenalectomy for bilateral adrenal tumours with cortisol excess	21
Addressing the educational needs of older adults with type 1 diabetes	20
Reversibility of congenital hypogonadotropic hypogonadism: lessons from a rare disease	20
Comorbidities and mortality in subgroups of adults with diabetes with up to 14 years follow-up: a prospective cohort study in Sweden	20
Peripheral CB1 receptor blockade for treatment of obesity	20
The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review	20
Analysis of cluster randomised trials as if they were individually randomised – Authors' reply	19
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase	19
Association between maternal diabetes and neurodevelopmental outcomes in children: a systematic review and meta-analysis of 202 observational studies comprising 56·1 million pregnancies	19
Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from th	19
Good news for patients with adrenocortical carcinoma from the ADIUVO trial	19
Does tirzepatide treatment improve skeletal muscle composition?	19
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement	19
Sugar, sugary drinks, and health: has the evidence achieved the sweet spot for policy action?	19
Mendelian randomisation at 20 years: how can it avoid hubris, while achieving more?	19
Correction to Lancet Diabetes Endocrinol 2023; 11: 905–14	19
The voices of lived experience in diabetes and endocrinology	19
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes	19
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial	19
What REDEFINE 5 signals for obesity trials in Asia and beyond	19